분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2013-04-24 14:20:45 , Hit : 2120
 Hepatitis C drug nears approval


23 Apr 2013 | 11:01 BST | Posted by Lauren Morello | Category: Drug discovery

Posted on behalf of Beth Mole.

A highly anticipated new drug for treating hepatitis C has sailed through its first phase III clinical trials, according to two papers published today in the New England Journal of Medicine.

Sofosbuvir, a new antiviral developed by Gilead Sciences of Foster City, California, is one of several drugs in the pipeline that could replace hepatitis C treatments that incorporate the immune-boosting drug interferon, which can cause harsh side effects including depression, anaemia and severe flu-like symptoms. Up to 170 million people worldwide are infected with blood-borne hepatitis C virus (HCV), including as many as 4 million people in the United States. Long-term exposure to the virus can cause chronic liver disease and cancer. Current therapies that combine the antiviral drug ribavirin and interferon cure up to 75% of those treated, but take as long as a year to do so.

Facing a lengthy drug regimen that can produce debilitating side effects, many patients — who may not develop liver damage for years — delay or refuse treatment. And with the promise of better drugs on the way, some doctors approve waiting.

The two papers published today suggest that the wait for improved hepatitis C treatment regimens may be coming to an end. Researchers led by Ira Jacobson of Weill-Cornell Medical College in New York report that a combination of sofosbuvir and ribavirin cured up to 78% of trial participants infected with two types of HCV — genotypes 2 and 3 — in as few as three months, without the need for interferon. That result is similar to outcomes from earlier phase II trials. Another team, led by Eric Lawitz of the Texas Liver Institute at the University of Texas Health Science Center in San Antonio, showed that a combination of sofosbuvir, ribavirin and interferon cured up to 90% of patients with HCV genotype 1, the most common variety.

“The results are certainly a step forward,” says David Thomas, a hepatitis C expert at the Johns Hopkins Center for Global Health in Baltimore, Maryland. But he adds that most physicians will be more excited to see results from an ongoing trial that is testing the effectiveness of treating HCV genotype 1 patients with sofosbuvir without interferon.

In the meantime, Gilead is seeking approval to market sofosbuvir in the United States. The company submitted an application for new drug approval to the US Food and Drug Administration (FDA) on 8 April.

Thomas says this first set of phase III trials puts sofosbuvir well on the path towards FDA approval. “This starts the clock,” he says, adding that he has already scheduled one of his HCV genotype 1 patients to come in for an interferon-free treatment regimen in December.









727   임자 있는 초원들쥐가 외간들쥐를 거들떠보지도 않는 이유: 후성유전학  이성욱 2013/06/05 3279
726   면역시스템이 유익세균과 평화로운 공존을 유지하는 방법  이성욱 2013/05/28 2492
725   TNF를 이용한 안전한 항종양 치료법  이성욱 2013/05/28 2656
724   Viruses in the gut protect from infection  이성욱 2013/05/22 2907
723   황우석을 넘어서: 미국의 과학자들, 체세포복제 기술로 인간 배아줄기세포 제조 성공  이성욱 2013/05/17 2462
722   Janssen's experimental drug for hepatitis C gets FDA fast track  이성욱 2013/05/15 2827
721   세상을 바꿀 10가지 기술  이성욱 2013/05/13 2330
720   Most Europeans share recent ancestors  이성욱 2013/05/10 2156
719   약물 저항성 세균을 파괴하는 방법  이성욱 2013/05/10 2552
718   분자생물학의 거성(巨星) 떨어지다; 프랑수아 자콥의 삶과 업적  이성욱 2013/05/09 2832
717   FDA fast tracks AbbVie hepatitis C drug  이성욱 2013/05/08 2196
716   Targeted drugs to tackle hepatitis C  이성욱 2013/05/06 1798
715   DNA: Celebrate the unknowns  이성욱 2013/04/26 1971
  Hepatitis C drug nears approval  이성욱 2013/04/24 2120
713   텔로머레이즈를 표적으로 삼는 새로운 항암 요법  이성욱 2013/04/24 3107
712   A pathogenic picornavirus acquires an envelope by hijacking cellular membranes  이성욱 2013/04/23 3003
711   BMS, Santaris Make Potentially $100M+ mRNA-Targeting Deal  이성욱 2013/04/17 2148
710   Scientists Map Elusive 3-D Structure of Telomerase Enzyme, Key Actor in Cancer, Aging  이성욱 2013/04/17 2305
709   Gilead seeks FDA OK for game-changing hepatitis C drug  이성욱 2013/04/10 2114
708   'RNA sponge' mechanism may cause ALS/FTD neurodegeneration  이성욱 2013/04/02 2604

[이전 10개] [1]..[21][22][23][24][25][26][27] 28 [29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN